The global atherectomy devices market size is expected to grow from $ 173 million in 2021 to reach $ 832 million in 2028 at a CAGR of 6.8%. atherectomy devices market is expected to have significant growth rate over forecast period owing to the increase in prevalence of the heart diseases around the world. According to World Health Organization, due to cardiovascular diseases, 17.7 Mn people died in the year 2015, and 7.4 Mn were due to coronary heart diseases. Market is consolidated due to the presence of the strong players. Companies are using the strategies such as acquisitions and collaborations to increase their market share. For instance, In May 2014, Volcano Corporation (subsidiary of Koninklijke Philips N.V.) acquired the atherectomy device producer, AtheroMed, Inc. to strengthen their market share. Similarly, In May 2014, Boston Scientific Corporation strengthened its product portfolio in peripheral vascular devices by the acquisition of Interventional business of Bayer AG for $ 415 Mn in cash. Furthermore, market players also investing in the R&D to develop the new and invasive products by adopting the new technologies. Atherectomy is a minimally invasive surgery to remove the atherosclerotic plaque from arteries. Atherosclerotic plaque either localized in coronary or peripheral atrial vasculature and many have different characteristics based on the texture. Atherosclerotic devices are used for atherectomy. There are various atherectomy devices which are designed based on their mechanisms such as cut, save, sand or vaporize the plaques and have different indications. Atherectomy is an alternative to angioscopy and it is also used for the coronary artery disease.
In September 2017, Avinger, Inc. has received CE Mark for its Pantheris Lumivascular atherectomy System to treat in-stent restenosis.
In March 2017, Cardiovascular Systems, Inc. got approval for its Diamondback 360 Coronary OAS Micro Crown, an orbital atherectomy system from Japan’s Ministry of Health, Labor and Welfare (MHLW).